Comorbidities in the psoriasis level and moderate in Hospital "Teodoro Maldonado Carbo" guayaquil – ecuador 2017 - 2018
Keywords:
Psoriasis, comorbidities, BMI, hypertension, glucoses, diabetes type IIAbstract
Introduction.- Psoriasis is a chronic disease of immune origin that affects the skin, mucosae membranes, scalp, nails with a genetic pre- disposition and can even compromise joints.
In Ecuador, there are not epidemiological dates or identification of co-morbidities at the national level of the number of people affected by these diseases.
Materials and methods.- This words is a retrospective study, observational, analytical cohort study was carried out in 239 patients with mild and moderate psoriasis by 5.490 total who were registered in the Dermatology department of the speciality Hospital in the social security Ecuadorian Institute Dr. Teodoro Maldonado Carbo” during 2017 until 2018.
Result.- The 239 patients, the prevalence of mild and moderate psoriasis was 4.3%, the mean age was 52.98 years old, of these patients 16.3% had high blood pressure, 7.1% had hypertension plus diabetes type 2, 1.3% polyarthritis like co-morbilities. In the analytical T test was shown that increase in weight and glucose 0.000< P=0.05 turned out to be detrimental factorin this type of disease. The relative risk BMI 31>1 and leukocytes 91.6 >1, it was shown that some had predisposition to infection in scaling-type lesion.
Discussion. - The affectation of comorbidities such as overweight due to degree of diet rich feeding in fat and carbohydrates, these patients presented high glucoses, altered liver tests and hypertension, especially with diagnoses of diabetes type 2. It´s recommended to evaluate the types of therapies used in the IESS Hospital that aren´t solving the therapeutic clinical part. Also do a good nutritional control status to reduce their co-morbidities that complicate their clinical and therapeutic picture.
Downloads
References
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370:263-71.
Raychaudhuri, SK; Maverakis, E; Raychaudhuri, SP (2014 Apr-May). «Diagnosis and classification of psoriasis». Autoimmun Rev 13 (4-5): 490-5
Nestle FO, Kaplan DH, Barker J. Mechanisms of disease: Psoriasis. N Engl J Med. 2009 Jul 30; 361(5):496-509.
Ordóñez J, Palacios A, Londoño A, Jiménez S. Medición de la calidad de vida por medio del Dermatology Life Quality Index en pacientes con psoriasis: una revisión sistemática. Rev Asoc Colomb Dermatol. 2013; 21:305-13.
Reichrath, J., Perez, A., Muller, S.M., Chen, T.C., Kerber, A., Bahmer, F.A., Holick, M.F. 1997. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: An immunohistological evaluation. Acta Derm. Venereol. 77:268.
J. H. Saurat et al., «Champion Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis», en Br J Dermatol. 158: 435-436, y 558-566, 2008.
Marc Juliá Manresa, Juan Antonio Romero Moreno: Tratamientos tópicos de la psoriasis: actualización. Med Cutan Iber Lat Am 2005; 33(4); 147-157
Carrascosa JM, Rocamora V, Fernandez-Torers R, Jiménez-Puya R, Moreno JC, Coll-Pulgserver N, Fonseca E. “Obesidad y psoriasis: naturaleza inflamatoria de la obesidad, relación entre psoriasis y obesidad e implicaciones terapéuticas”. Actas Dermo Sifiliogr 2014; 105(1): 31-44
https://www.ecuadorencifras.gob.ec/encuesta-nacional-de-salud-y-nutricion.
Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. “Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis”. Arch Dermatol 2012; 148(9): 995-1000.
Huskie J, Alendar F. “Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis”. Bosn J Basic Med Sci 2007; 7(2): 103-106
Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PloS one 2012, 7(12): 5293.
Gaceta medica de Mexico, la psoriasis de la investigacion basica y clinica al desarrollo de nuevos tratamientos. Esquivel-Garcia, Roberto; Estevez-Delgado, Gabino; Rodriguez-Orozco, Alain Raimundo; et ál 2018. Vol.154 No 4; 502-508
Boletín Farmaco-terapéutico de Castilla-La mancha. Actualización en el tratamiento de la psoriasis. Flor García A., Martínez Valdivieso L,Menéndez Ramos F, Barrera Hernandez D,mejía Recuero M, Barrera Hernández D 2013. Vol XIV No1 1-9
Evaluación de la eficiencia de los tratamientos biológicos en la psorisis moderada a grave en España: análisis de corte por número necesario a tratar. Nunez, M; Huete, T; de la Cueva, P; Sacristan, J A; Hartz, S; Dilla, T. Actas dermo-sifiliograficas 2019. Vol. 110 No 7: 546-553
Successful therapy of plaque type psoriais with secukinumab in patiens with multiple comorbidities treated with previos biologic therapies Lasagni Claudia; Bigi, Laura; Conti, Andrea; Pellacani, Giovanni. journal of Dermatology Treatment 2018. Vol 29: 5-8.
Pharmacoepidemiology and drug safety. Comorbidities, infections and treatment patterns in psoriasis patients: A retrospective analysis of a large United 9States electronic health record database. Varsos, G ; Peyerl, FW ; Shen, M ; Lodaya, K ; Gannu, L ; Shenoy, A ; Hayashida, DK ; D'Souza, F 2019 Vol 28: 269-270
Gelfand, J.M.; Weinstein, R.; Porter, S.B.; Neimann, A.L.; Berlin, J.A.; Margolis, D.J. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch. Dermatol. 2005, 141, 1537–1541.
Parisi, R.; Symmons, D.P.; Griffiths, C.E.; Ashcroft, D.M. Identification and Management of Psoriasis and Associated ComorbidiTy Project Team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013, 133, 377–385.
Carrascosa, J.M.; Rocamora, V.; Fernandez-Torres, R.M.; Jimenez-Puya, R.; Moreno, J.C.; Coll-Puigserver, N.; Fonseca, E. Obesity and psoriasis: Inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014, 105, 31–44.
Harari, M.; Shani, J.; Hristakieva, E.; Stanimirovic, A.; Seidl, W.; Burdo, A. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea. Int. J. Dermatol. 2000, 39, 913–918.
Kim, C.R.; Lee, J.H. An observational study on the obesity and metabolic status of psoriasis patients. Ann. Dermatol. 2013, 25, 440–444.
Debbaneh, M.; Millsop, J.W.; Bhatia, B.K.; Koo, J.; Liao, W. Diet and psoriasis, part I: Impact of weight loss interventions. J. Am. Acad. Dermatol. 2014, 71, 133–140
Okorodudu, D.O.; Jumean, M.F.; Montori, V.M.; Romero-Corral, A.; Somers, V.K.; Erwin, P.J.; Lopez-Jimenez, F. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: A systematic review and meta-analysis. Int. J. Obes. (Lond.) 2010, 34, 791–799
Di Renzo, L.; Saraceno, R.; Schipani, C.; Rizzo, M.; Bianchi, A.; Noce, A.; Esposito, M.; Tiberti, S.; Chimenti, S.; De Lorenzo, A. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol. Ther. 2011, 24, 446–451.
Barrea, L.; Macchia, P.E.; Di Somma, C.; Napolitano, M.; Balato, A.; Falco, A.; Savanelli, M.C.; Balato, N.; Colao, A.; Savastano, S. Bioelectrical phase angle and psoriasis: A novel association with psoriasis severity, quality of life and metabolic syndrome. J. Transl. Med. 2016, 14, 130.
Al-Mutairi, N.; Nour, T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial. Expert. Opin. Biol. Ther. 2014, 14, 749–756
Upala, S.; Sanguankeo, A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: A systematic review and meta-analysis. Int. J. Obes. (Lond.) 2015, 39, 1197–1202.
Mattozzi, C.; Paolino, G.; Richetta, A.G.; Calvieri, S. Psoriasis, vitamin D and the importance of the cutaneous barrier’s integrity: An update. J. Dermatol. 2016, 43, 507–514.
Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52:23-6.
DiBonaventura Md, Wagner S, Waters H, Carter C. Treatment patterns and perceptions of treatment attributes, satisfaction and effectiveness among patients with psoriasis. J Drugs Dermatol. 2010;9:938-44.
Grozdev I, Kast D, Cao L, Carlson D, Pujari P, Schmotzer B, et al. Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol. 2012;132:1111-6
Love TJ, Quereshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey 2003-2006. Arch Dermatol 2011; 147:419-24.
Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010; 90:23-26.
Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a
case control study. J Am Acad Dermatol 2007; 56:629-34.
Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension a prospective study of US
female nurses. Arch Dermatol 2009; 145:379-82.
Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitc J. Association between psoriasis and the
metabolic syndrome- a cross-sectional study. Dermatology 2008; 216:152-5.
Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 2015; 151: 432–438.
Nast A, Boehncke WH, Mrowietz U et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2012; 304: 87–113.
Smith CH, Jabbar-Lopez ZK, Yiu ZZ et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017; 177: 628–636.
Suárez-Fariñas M, Li K, Fuentes-Duculan J et al. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 2012; 132:2552-64.
Fleming P, Kraft J, Gulliver WP et al. The relationship of obesity with the severity of psoriasis: a systematic review. J Cutan Med Surg 2015; 19:450-6.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496-509.
Bernstein LE, Berry J, Kim S et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006; 166:902-8.
McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73:349-56.
Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012; 26 Suppl 2:3-11.
Boehncke S, Thaci D, Beschmann H et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157:1249-51.
Prignano F, Ricceri F, Pescitelli L et al. Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin 2009; 25:2311-6.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors retain the rights to the articles and are therefore free to share, copy, distribute, perform and publicly communicate the work on their personal websites or in institutional repositories, after publication in this journal, as long as they provide information bibliography that certifies its publication in this journal.
The works are under one
